Press Releases

Solasia Pharma KK officially announced today that the organoarsenic drug DARVIAS ® as Ministry of Health, Labor and Welfare  for the treatment of relapsed or refractory peripheral T-cell lymphoma (IM "PTCL" for short) has been approved. Solasia submitted the corresponding application to the MHLW in Japan in June 2021. In October 2021, Nippon Kayaku Co., Ltd. (TSE: 4272; HQ: Tokyo, Japan; President: Atsuhiro Wakumoto) signed a license agreement with marketing rights to DARVI

Medicure Inc.  a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce that the following individuals were elected as directors at its Annual General Meeting of shareholders held on June 16, 2022:  Dr. Albert Friesen, Gerald McDole, Brent Fawkes, Dr. Arnold Naimark, Peter Quick and James Kinley.  In addition, the shareholders re-appointed Ernst & Yo

Yseop, the world-leading AI software company and pioneer in Natural Language Processing (NLP), today announced that Sanofi, the global healthcare company, has chosen to scale its natural language generation (NLG) capabilities with Yseop. Sanofi will use the platform to accelerate its clinical study submission processes and bring new treatments to patients faster. Sanofi is one of the first pharmaceutical firms to leverage NLG in their clinical trial documents authoring workflows and

Zura Bio Limited, a clinical-stage biotechnology company focused on developing novel medicines for immune disorders, and JATT Acquisition Corp. (“JATT”) (NYSE: JATT, JATT.U, JATT.WS), a publicly traded special purpose acquisition company (“SPAC”) formed for the purpose of acquiring or merging with one or more businesses, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be rena

Yseop, the world-leading AI software company and pioneer in Natural Language Processing (NLP), today announced that Sanofi, the global healthcare company, has chosen to scale its natural language generation (NLG) capabilities with Yseop. Sanofi will use the platform to accelerate its clinical study submission processes and bring new treatments to patients faster. Sanofi is one of the first pharmaceutical firms to leverage NLG in their clinical trial documents authoring workflows and

Inozyme Pharma, Inc.a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced a partnership with Rady Children’s Institute for Genomic Medicine (RCIGM) to advance and evaluate a novel newborn screening technology to facilitate diagnosis of genetic diseases. The partnership includes several leading genomics, biotechnology companies and patient advocacy groups and focuses specifically on a diagnostic

Horizon Therapeutics plc  today announced that it has submitted a regulatory filing to the Brazil National Health Surveillance Agency (ANVISA) for UPLIZNA for the treatment of adult patients with anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD). “This regulatory submission is an important milestone as we continue to expand our commitment to NMOSD patients around the world,” said Vikram Karnani, executive vice

Pherecydes Pharma (FR0011651694 - ALPHE), a biotech company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announced today the enrollment of the 1st patient in the PhagoDAIR Phase II clinical trial. PhagoDAIR is the world's first study of phage therapy conducted in osteoarticular infections on prostheses caused by Staphylococcus aureus (S. aureus). Its protocol was approved by the ANSM (French National Agency for t

Covis Pharma GmbH, an affiliate of Group S.à r.l.  announced today that the U.S. Food & Drug Administration (FDA) anticipates holding a meeting of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee (ORUDAC) on October 17-19, 2022, to conduct a hearing about the future of Makena® (hydroxyprogesterone caproate injection). More information about the structure of the hearing can be found here. Prior to the hearing, FDA will publish a notice in the Federal Regis

InfuSystem Holdings, Inc.  a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced a national sales and marketing agreement with Ventis Pharma, a world leader in advancing surgical and chronic pain management solutions. The partnership will focus on sales and marketing of Ventis Pharma’s patented Endura-Kit™ brand of Enduracaine™, a local anesthetic compound. End